🇺🇸 FDA
Patent

US 12268673

Anhydrous compositions of mTOR inhibitors and methods of use

granted A61KA61K31/436A61K47/08

Quick answer

US patent 12268673 (Anhydrous compositions of mTOR inhibitors and methods of use) held by PALVELLA THERAPEUTICS, INC. expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PALVELLA THERAPEUTICS, INC.
Grant date
Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/436, A61K47/08, A61K47/10, A61K47/12